<DOC>
	<DOCNO>NCT00618735</DOCNO>
	<brief_summary>The purpose study see daily twice daily administration BIIB021 tolerate patient advance solid tumor .</brief_summary>
	<brief_title>Once Twice Daily Administration BIIB021 Subjects With Advanced Solid Tumors</brief_title>
	<detailed_description>Heat shock protein 90 ( HSP90 ) inhibitor anticipate clinical activity solid tumor Hsp90 require folding , activation , assembly many protein involve cancer cell survival , proliferation , metastasis . The maximum tolerated dose ( MTX ) BIIB021 administer twice weekly phase I study subject advance solid tumor define 600mg . It reasonable safety perspective desirable pharmacokinetic perspective evaluate frequent dosing interval solid tumor goal providing sustain complete inhibition Hsp90 .</detailed_description>
	<criteria>Subjects histologically cytologically confirm solid tumor fail refused standard therapy approve therapy available . Age great equal 18 year time inform consent . ECOG performance status less equal 2 . Lab value consistent adequate renal , hepatic , bone marrow function . Prior antitumor therapy , include prior experimental agent approve antitumor small molecule biologics within 28 day associate toxicity resolve eligibility level . Subjects know brain metastasis . Concurrent severe uncontrolled medical disease . Must utilize effective contraception .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>